Literature DB >> 9520235

Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain.

F Benedetti1, S Vighetti, M Amanzio, C Casadio, A Oliaro, B Bergamasco, G Maggi.   

Abstract

The treatment of neuropathic pain with opioid analgesics is a matter of controversy among clinicians and clinician scientists. Although neuropathic pain is usually believed to be only slightly responsive to opioids, several studies show that satisfactory analgesia can be obtained if adequate doses are administered. In the present study, we tested the effectiveness of buprenorphine in 21 patients soon after thoracic surgery (nociceptive postoperative pain) and 1 month after surgery in the same 21 patients who developed postthoracotomy neuropathic pain with a burning, electrical and shooting quality. According to a double-blind randomized study, the analgesic dose (AD) of buprenorphine needed to reduce the long-term neuropathic pain by 50% (AD50) was calculated and compared to the AD50 in the immediate postoperative period. We found that long-term neuropathic pain could be adequately reduced by buprenorphine. However, the AD50 in neuropathic pain was significantly higher relative to the AD50 in the short-term postoperative pain, indicating a lower responsiveness of neuropathic pain to opioids. We also found a strict relationship between the short-term and long-term AD50, characterized by a saturating effect. In fact, if the AD50 soon after surgery was low, the AD50 increase in the long-term neuropathic pain was threefold. By contrast, if the AD50 soon after surgery was high, the AD50 in neuropathic pain was only slightly increased. This suggests that, though neuropathic pain is indeed less sensitive to opioids, in some neuropathic patients a large amount of opioid resistance is already present in other painful conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520235     DOI: 10.1016/s0304-3959(97)00172-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  Rewarding electrical brain stimulation in rats after peripheral nerve injury: decreased facilitation by commonly abused prescription opioids.

Authors:  Eric E Ewan; Thomas J Martin
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

2.  Cannabinoids for chronic pain.

Authors:  Steven P Cohen
Journal:  BMJ       Date:  2008-01-08

Review 3.  Tramadol for neuropathic pain in adults.

Authors:  Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

4.  Treatment of pain in children after limb-sparing surgery: an institution's 26-year experience.

Authors:  Doralina L Anghelescu; Linda L Oakes; Gisele M Hankins
Journal:  Pain Manag Nurs       Date:  2010-09-20       Impact factor: 1.929

Review 5.  Drug infusions for the diagnosis and treatment of chronic pain.

Authors:  David A O'Gorman; Srinivasa N Raja
Journal:  Curr Pain Headache Rep       Date:  2002-12

Review 6.  Buprenorphine for neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Cathy Stannard; Dominic Aldington; Peter Cole; Roger Knaggs
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

7.  Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury.

Authors:  Chun-Yi Lee; Federico M Perez; Wei Wang; Xiaowei Guan; Xiuli Zhao; Janet L Fisher; Yun Guan; Sarah M Sweitzer; Srinivasa N Raja; Yuan-Xiang Tao
Journal:  Eur J Pain       Date:  2011-02-09       Impact factor: 3.931

8.  Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain.

Authors:  Eric E Ewan; Thomas J Martin
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

9.  Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.

Authors:  Ozgur Gunduz; Cagatay Oltulu; Rabia Guven; Dilek Buldum; Ahmet Ulugol
Journal:  Neurol Sci       Date:  2011-09-10       Impact factor: 3.307

10.  On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Authors:  Ronald J Tallarida; Alan Cowan; Robert B Raffa
Journal:  Drug Alcohol Depend       Date:  2010-01-12       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.